Last reviewed · How we verify
CureXcell
CureXcell is a recombinant human thrombolytic enzyme.
CureXcell is a recombinant human thrombolytic enzyme. Used for Ischemic stroke, Pulmonary embolism.
At a glance
| Generic name | CureXcell |
|---|---|
| Sponsor | Macrocure Ltd. |
| Drug class | Thrombolytic |
| Target | Fibrin |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by dissolving blood clots through enzymatic degradation of fibrin. This process is crucial in treating conditions like ischemic stroke and pulmonary embolism.
Approved indications
- Ischemic stroke
- Pulmonary embolism
Common side effects
- Hemorrhage
- Allergic reactions
- Fever
Key clinical trials
- Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes (PHASE3)
- Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers (PHASE3)
- A Post-marketing Observational Study of Cell Therapy for Chronic Wounds
- The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CureXcell CI brief — competitive landscape report
- CureXcell updates RSS · CI watch RSS
- Macrocure Ltd. portfolio CI